Literature DB >> 18941252

Strategic nonmyeloablative conditioning: CD154:CD40 costimulatory blockade at primary bone marrow transplantation promotes engraftment for secondary bone marrow transplantation after engraftment failure.

Hong Xu1, Yiming Huang, Paula M Chilton, Lala-Rukh Hussain, Michael K Tanner, Jun Yan, Suzanne T Ildstad.   

Abstract

There is an increased risk of failure of engraftment following nonmyeloablative conditioning. Sensitization resulting from failed bone marrow transplantation (BMT) remains a major challenge for secondary BMT. Approaches to allow successful retransplantation would have significant benefits for BMT candidates living with chronic diseases. We used a mouse model to investigate the effect of preparative regimens at primary BMT on outcome for secondary BMT. We found that conditioning with TBI or recipient T cell lymphodepletion at primary BMT did not promote successful secondary BMT. In striking contrast, successful secondary BMT could be achieved in mice conditioned with anti-CD154 costimulatory molecule blockade at first BMT. Blockade of CD154 alone or combined with T cell depletion inhibits generation of the humoral immune response after primary BMT, as evidenced by abrogation of production of anti-donor Abs. The humoral barrier is dominant in sensitization resulting from failed BMT, because almost all CFSE-labeled donor cells were killed at 0.5 and 3 h in sensitized recipients in in vivo cytotoxicity assay, reflecting Ab-mediated cytotoxicity. CD154:CD40 costimulatory blockade used at primary BMT promotes allogeneic engraftment in secondary BMT after engraftment failure at first BMT. The prevention of generation of anti-donor Abs at primary BMT is critical for successful secondary BMT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941252      PMCID: PMC2767528          DOI: 10.4049/jimmunol.181.9.6616

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Alpha beta TCR+ T cells play a nonredundant role in the rejection of heart allografts in mice.

Authors:  B G Exner; X Que; Y M Mueller; M A Domenick; M Neipp; S T Ildstad
Journal:  Surgery       Date:  1999-08       Impact factor: 3.982

2.  Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand.

Authors:  T G Markees; N E Phillips; R J Noelle; L D Shultz; J P Mordes; D L Greiner; A A Rossini
Journal:  Transplantation       Date:  1997-07-27       Impact factor: 4.939

3.  Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol.

Authors:  Christoph Domenig; Alberto Sanchez-Fueyo; Josef Kurtz; Sophoclis P Alexopoulos; Christophe Mariat; Megan Sykes; Terry B Strom; Xin Xiao Zheng
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

Review 4.  CD40 and CD154 in cell-mediated immunity.

Authors:  I S Grewal; R A Flavell
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

5.  In vivo depletion of host CD4+ and CD8+ cells permits engraftment of bone marrow stem cells and tolerance induction with minimal conditioning.

Authors:  B G Exner; Y L Colson; H Li; S T Ildstad
Journal:  Surgery       Date:  1997-08       Impact factor: 3.982

6.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

7.  A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.

Authors:  Y L Colson; S M Wren; M J Schuchert; K D Patrene; P C Johnson; S S Boggs; S T Ildstad
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

8.  Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice.

Authors:  H Li; C L Kaufman; S S Boggs; P C Johnson; K D Patrene; S T Ildstad
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

9.  Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide.

Authors:  Mark Girgis; Chris Hallemeier; William Blum; Randy Brown; Hsiu-San Lin; Hanna Khoury; L Tim Goodnough; Ravi Vij; Steve Devine; Marita Wehde; Stacey Postma; Aarti Oza; John Dipersio; Douglas Adkins
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

Review 10.  Induction of immunologic tolerance for transplantation.

Authors:  A A Rossini; D L Greiner; J P Mordes
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

View more
  4 in total

1.  A critical role for the TLR4/TRIF pathway in allogeneic hematopoietic cell rejection by innate immune cells.

Authors:  Hong Xu; Jun Yan; Ziqiang Zhu; Lala-Rukh Hussain; Yiming Huang; Chuanlin Ding; Larry D Bozulic; Yujie Wen; Suzanne T Ildstad
Journal:  Cell Transplant       Date:  2012-11-08       Impact factor: 4.064

2.  Sensitized recipients exhibit accelerated but not hyperacute rejection of vascularized composite tissue allografts.

Authors:  Shengli Wu; Hong Xu; Bo Chen; Yujie Wen; Olayemi M Ikusika; Ashley Ocker; Hong Zhao; Suzanne T Ildstad
Journal:  Transplantation       Date:  2011-09-27       Impact factor: 4.939

3.  Lack of antidonor alloantibody does not indicate lack of immune sensitization: studies of graft loss in a haploidentical hematopoietic cell transplantation swine model.

Authors:  Raimon Duran-Struuck; Abraham Matar; Rebecca Crepeau; Ashley Gusha; Marian Schenk; Isabel Hanekamp; Vimukthi Pathiraja; Thomas R Spitzer; David H Sachs; Christene A Huang
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-11       Impact factor: 5.742

4.  Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning.

Authors:  Hong Xu; Ziqiang Zhu; Yiming Huang; Larry D Bozulic; Lala-Rukh Hussain; Jun Yan; Suzanne T Ildstad
Journal:  Transplantation       Date:  2012-03-15       Impact factor: 4.939

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.